Introduction {#Sec1}
============

Studies on heterocyclic compounds containing bridgehead nitrogen atom particularly those holding (1,2,4,5)-tetrazine, (1,2,4)-triazole and (1,2,4)-triazine derivatives have received much interest recently as they can be used in a variety of applications, especially in the medicinal field. For example, many of 1,2,4-triazole rings are found into a wide range of pharmaceutical drugs including antimicrobial agents^[@CR1],[@CR2]^, antifungal^[@CR3],[@CR4]^, antibacterial^[@CR5]--[@CR9]^, antimycobacterial^[@CR10]^, antiviral^[@CR11],[@CR12]^, anticancer^[@CR13]^, antitubercular^[@CR14]^, antimycotic activity^[@CR15],[@CR16]^, antimigraini agents, anti-inflammatory and analgesic^[@CR17]--[@CR19]^, anticonvulsants^[@CR20]^, antinociceptive^[@CR21]^, anti-ureaese^[@CR22]^, antioxidant^[@CR23]^, CNS stimulants, and antidepressant^[@CR24]^ properties.

1,2,4-triazole rings possess not only diverse pharmacological activities but also to have herbicidal, insecticidal, plant growth regulatory and antifungal activities^[@CR25]^. Thus, for many years, the biochemistry of these molecules has been investigated^[@CR26]^. Also, Heterobicyclic nitrogen systems containing 1,2,4-Triazines derivatives and 1,2,4-Triazines themselves have been found to display a diversity of biological applications such as Lamotrigine as anti-epileptic drug^[@CR27]^, Tirapazamine as anti-tumor^[@CR28]^, and fused 1,2,4--triazines as antimicrobial^[@CR29],[@CR30]^, anti--viral^[@CR31]^, antimycobacterial^[@CR32]^, anxiolytic^[@CR33]^ and antidepressant^[@CR34]^ activities. They also have shown anti--HIV and anticancer activities^[@CR35]^. Moreover, derivatives of the tetrazine ring have attracted extensive attention from numerous research groups because of their interesting and diverse biological activities as antitumor and antiviral^[@CR36]^. In this respect, Abdel-Rahman *et al*.^[@CR37]--[@CR39]^ found that 1,2,4-triazines, 1,2,4-triazoles and/or 1,2,4-triazolo-1,2,4,5-tetrazines can be used as a molluscicidal and antimicrobial as well as they have anticancer drugs activity. Due to their novel energetic properties^[@CR25],[@CR26],[@CR40]^, organic compounds with high-nitrogen content currently attract the attention of many researchers.

In light of these remarks, researchers were prompted to design and synthesize new drugs containing heterocyclic compounds, especially, those containing triazoles, triazines and tetrazines rings as a result of the fact that Nitrogen--Nitrogen bond is difficult to be produced in living organisms in addition to its therapeutic activities. Thus, because of these remarks, the target of this work is to synthesize some new 1,2,4-triazole fused with 1,2,4-triazine and/or 1,2,4,5-tetrazine nucleus holding different types of functional groups to enhance their biological activity, in a hope to design a semi-drug. To demonstrate whether COX-II was a potential target for our newly prepared compounds, molecular modeling studies have been conducted on these compounds.

Experimental {#Sec2}
============

General Method for the preparation of novel 1,2,4-triazolo\[4,3-b\]\[1,2,4,5\]tetrazines and 1,2,4-triazolo\[4,3-b\]\[1,2,4\]triazines {#Sec3}
--------------------------------------------------------------------------------------------------------------------------------------

A mixture of compounds **1a,b**, and **2a,b** with 1:1 molar ratio in 100 mL Ethanol-DMF was refluxed for 5 h, then poured into ice and the formed solids were collected by filtration and crystallized to give compounds **3a to 3d**, respectively. To prepare the compounds **5a--d**, a mixture of (0.01 mol) of **3a--d** and (0.01 mol) of chloromethyl-diphenylphosphanoxide in (100 mL) THF with (0.5 mL) TEA was refluxed for 5 h and cooled. The obtained solids were then were collected by filtration and crystallized to give **5a--d**, respectively. When (0.01 mol) of **3a--d** were mixed with (0.01 mol) of phenacyl bromide in 50 mL from 5% ethanolic KOH and heated under reflux for 3 h, then poured into ice and acidified with few drops of HCl. The yielded solids were filtered and crystallized to give compounds **6a--d** respectively. Compounds **7a--d** were prepared by mixing a mixture of (0.01 mol) **3a--d** and (0.01 mol) sodium pyruvate, in 10 mL H~2~O with 50 mL 5% aqueous NaOH. After that, the mixture was refluxed for 3 h, then poured into ice and acidified with few drops of HCl. The products filtered and recrystallized to give **7a--d compounds** respectively. Equimolar ratio mixture of both compounds **3a--d** and diethyl oxalate in 100 mL THF was refluxed for 5 h and cooled. The obtained products were filtered and crystallized from the proper solvent to give **8a--d** respectively. A mixture of each of **1a,b** (0.01 mol) and hydrazine hydrate (0.04 mol) in ethanol (100 mL) was refluxed for 6 h and cooled. Then a few drops of acetic acid were added. The produced solids were filtered off and recrystallized to give **9a,b** respectively^[@CR41],[@CR42]^. When the equimolar ratio of each of **9a,b** and triethylphosphite in tetrahydrofuran (100 mL) and triethylamine (0.5 mL) was refluxed 6 h and cooled. The obtained solids were filtered off and recrystallized to give compounds **10a,b** respectively. A mixture of **9a,b** (0.01 mol) and triethylorthoformate (0.012 mol) in tetrahydrofuran (100 mL) was refluxed for 6 h and cooled. The produced solids were filtered off and recrystallized to give **11a,b** respectively. The spectral data together with the physical constants of **11a,b** are listed below. A mixture of **9a,b** (0.01mole) and 2-chloro-6-fluorobenzeldehyde (0.01 mol) in ethanol (100 mL)/piperidine (0.5 mL) was refluxed 12 h and then cooled. The produced solids were filtered off and crystallized to give **12a,b** respectively. A mixture of each of **9a,b** (0.01 mol), CS~2~ (0.02 mol) in DMF (50 mL) was refluxed for 3 h and cooled, then poured onto the ice. The resulting solids so formed were filtered off and recrystallized to give **13a,b** respectively. A mixture of each of **9a,b** (0.01 mol) and ethyl chloroformate (0.012 mol) with tetrahydrofuran (100 mL) and triethylamine (0.5 mL, added dropwise) was refluxed for 3 h and then cooled. The solids obtained were filtered off and recrystallized to give **14a,b** respectively.

The first compound (**1)** was prepared by direct hydrazinolysis of 4-pyridyl-CONHNHCS~2~K according to Reid *et al*. reported method^[@CR43]^.

Characterization of the newly synthesized samples {#Sec4}
-------------------------------------------------

The spectral data together with the physical constants of all of the previously prepared compounds were identified as follows:

To confirm the occurrence of the reaction, Fourier transformer infrared (FTIR) spectrometer (a Perkin Lemer Spectrum RXI FT-IR systems No. 55529) was used. FT-IR spectra within the wavenumber ranged from 4000--600 cm^−1^ were recorded at room temperature in ATR discs.

^1^H/ ^13^C-NMR Spectra were recorded in (DMSO-*d*6) at 400 MHz with a Bruker NMR Advance DPX 400 MH Spectrometer. TMS was used as an internal reference. Chemical shifts were supposed to be due to the presence of the solvent.

The melting points of the synthesized compounds were determined by using SMP (Stuart Scientific melting point) (USA).

GCMS-Q 1000 Ex spectrometer was used to measure the mass spectra of the prepared materials. Shimadzu UV-visible 3101 PC Spectrophotometer was used to record the electronic absorption spectra of the synthesized materials in DMF.

### Antimicrobial activity {#Sec5}

A bacterial suspension having a density of about 1 to 2 ×10^8^ (CFU) colony-forming units/ mL was prepared by aging a single colony on an agar plate for 24 hours. The antibacterial activity of some newly synthesized compounds was investigated on Mueller-Hinton agar using Agar diffusion techniques at concentrations of 100, 50 and 25 μg/mL, respectively. Muller Hinton agar (MHA) plates were inoculated with test inoculum (E. coli, Pseudomonas aeruginosa and Staphylococcus aureus) of standard inoculum (0.5 McFarland). Nalidixic acid and Imipenem were used as a reference drug for bacteria. Briefly, MHA agar plates were inoculated with bacterial strains under sterile conditions, and disc (diameter = 8 mm) was loaded with 50 μL of the tested sample. The plate was incubated at 37 °C for 24 hours. Nalidixic acid and Imipenem were used as a reference drug for bacteria. After the incubation period, the antimicrobial agent usually diffuses into the agar and inhibits the germination and growth of the test microorganism, and then according to the Clinical Laboratory Standards (CLSI), the diameter of the growth-inhibiting zone was measured^[@CR44]^. The MICs of the prepared compounds were determined by the agar dilution plate technique following the standard procedure of the Clinical and Laboratory Standards^[@CR44]^. The MICs were calculated from the X-axis intercept of the linear graph between log (Inhibitory concentration) and the growth inhibitory zone area.

The fungal strain was grown in 5 mL Sabourad Glucose Broth (glucose: peptone; 40: 10) for 3--4 days to reach 10^5^ CFU/mL cells. Fungal cultures (0.1 mL) were spread evenly on Sabourad dextrose agar plates. The plates were inoculated with fungal strains under sterile conditions, and disc (diameter = 8 mm) was loaded with 50 μL of the test sample. The plate was then incubated at 30 °C for 3--4 days and according to the Clinical Laboratory Standards (CLSI), the diameter of the growth-inhibiting zone was measured^[@CR44]^. Nystatin was used as antifungal standard drug^[@CR45]^.

#### Anti-inflammatory activity of the newly synthesized compounds {#Sec6}

Carrageenan-induced paw edema method was used to evaluate the anti-inflammatory effect of the selected prepared compounds^[@CR46],[@CR47]^. Indomethacin drug as a suspension in 24 tweens 80 was used as the reference drug, using Winter *et al*. method^[@CR46],[@CR47]^. The inhibition percentage of inflammation was calculated using the following equation:$$\documentclass[12pt]{minimal}
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Microanalyses (CHNS elemental) and anti-inflammatory activity of the prepared compounds were carried out in the pharmaceutical Microbiology Department, National Center for Radiation Research and Technology (NCRRT), Nasr City, Egypt.

### Molecular docking {#Sec7}

Based on the results of antibacterial screening and the anti-inflammatory assay, docking of the most active compound **5d** and the positive control, **Nalidixic acid**, in case of antibacterial screening was performed with the binding site of DNA Gyrase (topoisomerase II) enzyme (PDB ID: 2XCT). Also, docking of compounds **10a,b, 12a,b** and the positive control **Indomethacin** in case of anti-inflammatory effect was performed with the binding site of COX-2 (PDB ID: 1CX2). Docking was done to shed light on their potential binding modes and investigate their similarity to the standard ligand binding modes^[@CR48]--[@CR50]^.

#### Molecular docking procedure {#Sec8}

X-ray crystal structure of DNA Gyrase (topoisomerase II) complexed with a Ciprofloxacin was determined at 3.35 Å resolution and X-ray crystal structure of COX-2 complexed with a selective inhibitor, sc-558 at 3 Å resolution. All molecular modeling calculations and docking studies were carried out using 'Molecular Operating Environment 2019.0101' software (MOE of Chemical Computing Group Inc., on a Core i7 2.2 GHz workstation) running on a Windows 10 PC.

#### Preparation of the targets (DNA Gyrase (topoisomerase II) enzyme and COX-2) {#Sec9}

The X-ray crystallographic structures of DNA Gyrase (topoisomerase II) enzyme (PDB ID: **2XCT**) and cyclo-oxygenase 2 (PDB ID: **1CX2**) were downloaded from the protein data bank (<http://www.rcsb.org/>)^[@CR51]^. The enzyme was prepared for docking study by removal of chain B, C and D of its dimmers, water molecules, and ligands that are not involved in the binding. The enzyme was then prepared using quick preparation protocol in MOE with default options.

#### Docking validation {#Sec10}

To confirm whether the applied docking protocol is valid or not, Re-docking of the co-crystallized ligand into the enzyme was done. Based on the binding mode and rmsd (root mean square deviation), the coordinates of the native ligand in the co-crystallized PDB file were compared with the coordinates of the greatest scoring docking pose of the native ligand. The docking validation results revealed a near-perfect alignment with the original ligand as attained from the resolved X-ray PDB file. In the case of antibacterial screening, docking validation was confirmed from the small root mean square deviation (rmsd = 0.3155) between the docked pose and the co-crystallized ligand (S (energy score) of −11.2658 kcal/mol). Docking validation was also demonstrated by the ability of the docking poses to restore the main interactions that occur between the co-crystallized ligand and the active site's hot spots, Manganese (Mn) atom and DG 5 of DNA Gyrase enzyme. In case of anti-inflammatory effect, the re-docked ligand showed a small root mean square deviation value (rmsd = 0.0215) between the docked compound and the co-crystallized ligand (S of −15.569 kcal/mol), they also showed a high ability to repeat the main interactions that occur between the co-crystallized ligand and the active site's hot spots, Arg513 and His90 of COX-II.

#### Active compounds preparation for docking {#Sec11}

Active compounds preparation for docking was done as follows: firstly, Marvin Sketch was used to built up the 2D structures of the docked ligands and copied onto MOE. This step is followed by 3D protonation of the active compounds structure. Then the systemic search was used for the running of the conformational analysis and then the smallest energetic conformer was selected. An identical docking protocol was applied with the ligand.

#### Running of docking {#Sec12}

Docking studies were performed using DNA Gyrase (topoisomerase II) enzyme co-crystallized with the native ligand of protein data bank file ID: **2XCT** (PDB ID: **2XCT**) and also COX-II enzyme co-crystallized with the native ligand of protein data bank file ID: **1CX2** (PDB ID: **1CX2**). Posing compounds **5d** and **Nalidixic acid**, in case of antibacterial screening, and compounds **10a,b, 12a,b** and the positive control **Indomethacin**, in case of anti-inflammatory effect, was scored by London dG scoring function, that was used for docking, and Triangle Matcher placement protocol. The docked compounds of the greatest scoring pose were documented. Interactions between ligand and receptor in the formed complexes were tested in both 3D and 2D styles.

Results and Discussion {#Sec13}
======================

The spectral data and physical constants of the newly synthesized compounds {#Sec14}
---------------------------------------------------------------------------

For compound (3a) (N^3^-(5-chloropyrimidin-2-yl)-5-phenyl-4H-1,2,4-triazole-3,4-diamine):Yield 68% crystal from dioxan; mp 213--215 ^o^C. Analysis calculated for C~12~H~10~ClN~7~ (287): C, 50.10; N, 34.08; H, 3.50; Cl, 12.32. The analyses found for the compound are: C, 50.16; H, 3.57; Cl, 12.30; N, 34.15). The UV spectrum gave \[λ~max~ (Log ε)\]: 372 nm. IR characteristic peaks appear at (ν cm^−1^): 3449, 3318 (NH~2~), 3189 (NH), 1601, 1581(C=N). ^1^H NMR characteristic peaks appear at δ ppm: 5.87(s, (2H), NH~2~), 4.0(s, (1H), NH), 8.05(s, 2H, (CH)-pyrimidine), 7.41--8.28 (m, 5H, CH-benzene). ^13^C NMR characteristic peaks appear at δ ppm: 119.0 (C5 of pyrimidine, C-Cl), 126.50,129.20 (C~2~ and C~3~ of benzene), 131.1 (C~4~ of benzene), 130.6 (C~1~ of benzene), 151.1 (C~5~ of triazole), 157.2 (C~2~ of triazole), 167.9 (C~2~ of pyrimidine), 156.8 (C~4\ and~ C~6~ of pyrimidine). MS (Int.%): 287 (5.1, M^+^), 271(12.5, M^+^ - NH~2~), 174 (22.5, M^+^ - 4-chloropyrimidyl), 159 (34.8, M^+^ - 4-chloropyrimidyl-NH), 128 (15.1, 4-chloropyrimidyl-NH), 113 (12.2, 4-chloropyrimidyl).For compound (3b) (N^3^-(5-chloropyrimidin-2-yl)-5-(pyridin-4-yl)-4H-1,2,4-triazole-3,4-diamine):Yield 61% crystal from dioxan; mp 222--225 ^o^C. Analysis calculated for C~11~H~9~ClN~8~ (288): C, 45.76; H, 3.14; Cl, 12.28; N, 38.81. The analyses found for the compound are: C, 45.70; H, 3.11; Cl, 12.30; N, 38.83). The UV spectrum gave \[λ~max~ (Log ε)\]: 374 nm. IR characteristic peaks appear at (ν cm^−1^): 3442, 3325 (NH~2~), 3200 (NH), 1601,1581(C=N). ^1^H NMR characteristic peaks appear at δ ppm: 5.77(s, (2H), NH~2~), 4.0(s, (1H), NH), 8.05(s, 2H, (CH)-pyrimidine), 8.75(d, (2H), (CH)-pyridine), 7.99(d, (2H), (CH)-pyridine). ^13^C NMR characteristic peaks appear at δ ppm: 119.0 (C5 of pyrimidine, C-Cl), 121.3,149.8 (C~2~ and C~3~ of pyridine), 134 (C~4~ of pyridine), 157.2 (C~5~ of triazole), 151.1 (C~2~ of triazole), 167.9 (C~2~ of pyrimidine), 156.8 (C~4~ and C~6~ of pyrimidine). MS (Int.%): 288 (11.7, M^+^), 272(8.4, M^+^ - NH~2~), 175 (18.9, M^+^ - 4-chloropyrimidyl), 160 (31.2, M^+^ - 4-chloropyrimidyl-NH), 128 (13.4, 4-chloropyrimidyl-NH), 113 (11.8, 4-chloropyrimidyl).For compound (3c) (N^3^-(5-bromopyrimidin-2-yl)-5-phenyl-4H-1,2,4-triazole-3,4-diamine):Yield 52% crystal from dioxan; mp 288--291 ^o^C. Analysis calculated for C~12~H~10~BrN~7~ (331): C, 43.39; H, 3.03; Br, 24.06; N, 29.52. The analyses found for the compound are: C, 43.40; H, 3.01; Br, 24.08; N, 29.55). The UV spectrum gave \[λ~max~ (Log ε)\]: 370(0.80)nm. IR characteristic peaks appear at (ν cm^−1^): 3440, 3350 (NH~2~), 3195 (NH), 1600, 1578 (C=N). ^1^H NMR characteristic peaks appear at δ ppm: 5.71(s, (2H), NH~2~), 3.7(s, (1H), NH), 8.53(s, 2H, (CH)-pyrimidine), 7.04--8.25(m, 5H, CH-benzene). ^13^C NMR characteristic peaks appear at δ ppm: 110.7 (C5 of pyrimidine, C-Br), 127.5,129.2 (C~2~ and C~3~ of benzene), 131.1 (C~4~ of benzene), 130.6(C~1~ of benzene), 157.2 (C~5~ of triazole), 151.1 (C~2~ of triazole), 168.4 (C~2~ of pyrimidine), 159.1 (C~4\ and~ C~6~ of pyrimidine). MS (Int.%): 331 (9.3, M^+^), 316 (9.1, M^+^ - NH~2~), 177 (22.3, M^+^ - 4-bromopyrimidyl), 162 (31.2, M^+^ - 4-bromopyrimidyl-NH), 170 (42.1, 4-bromopyrimidyl-NH), 155 (15.2, 4-bromopyrimidyl).For compound (3d) (N^3^-(5-bromopyrimidin-2-yl)-5-(pyridin-4-yl)-4H-1,2,4-triazole-3,4-diamine):Yield 48% crystal from dioxane; mp 257--259 ^o^C. Analysis calculated for C~11~H~9~BrN~8~ (332): C, 39.66; H, 2.72; Br, 23.98; N, 33.63 C, 39.66; H, 2.72; Br, 23.98; N, 33.63. The analyses found for the compound are: C, 39.62; H, 2.75; Br, 24.00; N, 33.65). The UV spectrum gave \[λ~max~ (Log ε)\]: 374(0.84) nm. IR characteristic peaks appear at (ν cm^−1^): 3452, 3367 (NH~2~), 3188 (NH), 1600,1568 (C=N). ^1^H NMR characteristic peaks appear at δ ppm: 5.68(s, (2H), NH~2~), 4.2(s, (1H), NH), 8.56(s, 2H, (CH)-pyrimidine), 8.82(d, (2H), (CH)-pyridine), 7.95(d, (2H), (CH)-pyridine). ^13^C NMR characteristic peaks appear at δ ppm: 110.7 (C5 of pyrimidine, C-Br), 121.3, 149.8 (C~2~ and C~3~ of pyridine), 134.0 (C~4~ of pyridine), 157.2 (C~5~ of triazole), 151.1 (C~2~ of triazole), 168.4 (C~2~ of pyrimidine), 159.1 (C~4~ and C~6~ of pyrimidine). MS (Int.%): 332 (13.8, M^+^), 317(11.1, M^+^ - NH~2~), 178 (19.8, M^+^ - 4-bromopyrimidyl), 163 (33.5, M^+^ - 4-bromopyrimidyl-NH), 170 (31.5, 4-bromopyrimidyl-NH).For compound (5a) (8-(5-chloropyrimidin-2-yl)-3,6,6-triphenyl-5,6,7,8-tetrahydro-\[1,2,4\]triazolo-\[3,4-f\] \[1--3,5\]triazaphosphinin-6-ol):Yield 56%, crystals from dioxan; mp 277--279 ^o^C. Analysis calculated for C~25~H~21~ClN~7~OP (501): C, 59.83; H, 4.22; Cl, 7.06; N, 19.53; P, 6.17. The analyses found for the compound are: C,59.80; H, 4.23; N,19.56; Cl, 7.08, P, 6.18. IR characteristic peaks appear at (ν cm^−1^): 3080(aromatic (CH)), 2925(aliphatic (CH)), 1650(P-OH), 1522(C=N). ^1^H NMR characteristic peaks appear at δ ppm: 2.8(s, 1H, OH), 2.0(s, (1H), NH), 3.1(s, (2H), CH~2~), 7.41--8.05(m, 15H, CH-benzene), 8.08(s, 2H, (CH)-pyrimidine). ^13^C NMR characteristic peaks appear at δ ppm: 119.0 (C~5~ of pyrimidine, C-Cl), 130.6 (C~1~ of benzene, C-triazole), 127.5 (C~2~ of benzene attached with triazole), 129.2 (C~3~ of benzene attached with triazole), 131.1 (C~4~ of benzene attached with triazole), 131.2 (C-P of benzene), 84 (N-C-P of triaziphosphine), 157.2 (C~5~ of triazole), 151.1 (C~2~ of triazole), 167.9 (C~2~ of pyrimidine), 156.6 (C~4~ and C~6~ of pyrimidine).For compound (5b) (8-(5-chloropyrimidin-2-yl)-3-(pyridine-4-yl)-6,6-diphenyl-5,6,7,8-tetrahydro\[1,2,4\]triazolo\[3,4-f\]\[1--3,5\]triazaphosphinin-6-ol):Yield 43%, crystals from dioxan; mp 300--302 ^o^C. Analysis calculated for C~24~H~20~ClN~8~OP (502):C, 57.32; H, 4.01; Cl, 7.05; N, 22.28; O, 3.18; P, 6.16. The analyses found for the compound are: C, 57.40; H, 3.98; N,22.30; Cl, 7.07, P, 6.18. IR characteristic peaks appear at (ν cm^−1^): 3078(aromatic (CH)), 2943(aliphatic (CH)), 1647(P-OH), 1518(C=N). ^1^H NMR characteristic peaks appear at δ ppm: 3.1(s, 1H, OH), 2.3(s, (1H), NH), 3.6(s, (2H), CH~2~), 7.35--8.09(m, 10H, CH-benzene), 8.21(s, 2H, (CH)-pyrimidine), 8.75(d, (2H), (CH)-pyridine), 7.99(d, (2H), (CH)-pyridine). ^13^C NMR characteristic peaks appear at δ ppm: 119.0 (C5 of pyrimidine, C-Cl), 134(C~4~ of pyridine), 121.3 (C~3~ and C~5~ of pyridine), 149.8 (C~2~ and C~6~ of pyridine), 131.2 (C-P of benzene), 131.2 (C~2~ and C~6~ of benzene), 128.7 (C~3,4,5~ of benzene), 84.3 (N-C-P of triaziphosphine), 157.2 (C~2~ of triazole), 151.1 (C~5~ of triazole), 167.9 (C~2~ of pyrimidine), 156.6 (C~4~ and C~6~ of pyrimidine).For compound (5c) (8-(5-Bromopyrimidin-2-yl)-3,6,6-triphenyl-5,6,7,8-tetrahydro \[1,2,4\]triazolo\[3,4-f\] \[1--3,5\]triazaphosphinin-6-ol):Yield 51%, crystals from dioxan; mp 222--225 ^o^C. Analysis calculated for C~25~H~21~BrN~7~OP (554): C, 54.96; H, 3.87; Br, 14.62; N, 17.95; O, 2.93; P, 5.67. The analyses found for the compound are: C, 54.94; H, 3.86; Br, 14.65; N, 18.00; O, 2.93; P, 5.70. IR characteristic peaks appear at (ν cm^−1^): 3073(aromatic (CH)), 2952(aliphatic (CH)), 1643(P-OH), 1519 (C=N). ^1^H NMR characteristic peaks appear at δ ppm: 3.3(s, 1H, OH), 2.4(s, (1H), NH), 3.6(s, (2H), CH~2~), 7.30--8.05(m, 15H, CH-benzene), 8.34(s, 2H, (CH)-pyrimidine). ^13^C NMR characteristic peaks appear at δ ppm: 110.7 (C-Br of pyrimidine), 130.6 (C~1~ of benzene, C-triazole), 127.5 (C~2~ and C~6~ of benzene attached with triazole), 129.2 (C~3~ and C~5~ of benzene attached with triazole), 131.1 (C~4~ of benzene attached with triazole), 131.2 (C-P of benzene), 84.3 (N-C-P of triaziphosphine), 157.2 (C~5~ of triazole), 151.1 (C~2~ of triazole), 168.4 (C~2~ of pyrimidine, C-N), 159.1 (C~4~ and C~6~ of pyrimidine).For compound (5d) (8-(5-Bromopyrimidin-2-yl)-3-(4-pyridin-4-yl)-6,6-triphenyl-5,6,7,8-tetrahydro\[1,2,4\]triazolo\[3,4-f\]\[1--3,5\]triazaphosphinin-6-ol):Yield 39%, crystals from dioxan; mp 267--269 ^o^C. Analysis calculated for C~24~H~20~BrN~8~OP (554): C, 54.96; H, 3.87; Br, 14.62; N, 17.95; O, 2.93; P, 5.67. The analyses found for the compound are: C, 54.94; H, 3.86; Br, 14.65; N, 18.00; O, 2.93; P, 5.70. IR characteristic peaks appear at (ν cm^−1^): 3073(aromatic (CH)), 2952(aliphatic (CH)), 1643(P-OH), 1519 (C=N). ^1^H NMR characteristic peaks appear at δ ppm: 3.3(s, 1H, OH), 2.4(s, (1H), NH), 3.6(s, (2H), CH~2~), 7.30--8.05(m, 15H, CH-benzene), 8.34(s, 2H, (CH)-pyrimidine). ^13^C NMR characteristic peaks appear at δ ppm: 110.7 (C-Br of pyrimidine), 130.6 (C~1~ of benzene, C-triazole), 127.5 (C~2~ and C~6~ of benzene attached with triazole), 129.2 (C~3~ and C~5~ of benzene attached with triazole), 131.1 (C~4~ of benzene attached with triazole), 131.2 (C-P of benzene), 84.3 (N-C-P of triaziphosphine), 157.2 (C~5~ of triazole), 151.1 (C~2~ of triazole), 168.4 (C~2~ of pyrimidine, C-N), 159.1 (C~4~ and C~6~ of pyrimidine).For compound (6a) (8-(5-chloropyrimidin-2-yl)-6-phenyl-3-(pyridin-2-yl)-7,8-dihydro-\[1,2,4\]triazolo-\[4,3-b\] \[1,2,4\]triazine):Yield 51%, crystals from dioxane/diluted by methanol, mp 171--173^o^C. Analysis calculated for C~19~H~13~ClN~8~ (388): C, 58.69; H, 3.37; Cl, 9.12; N, 28.82. The analyses found for the compound are: C, 58.7; H, 3.35; N, 28.9; Cl, 9.15. IR characteristic peaks appear at (ν cm^−1^): 3079.20, 2966 cm^−1^ (aromatic & aliphatic (CH)), 1522(C=N). ^1^H NMR characteristic peaks appear at δ ppm: 3.13(s, (2H), CH~2~) triazine ring, 8.05(s, 2H, (CH)-pyrimidine), 7.52--7.94(m, 5H, CH-benzene), 8.38 (d, 1H, CH- pyridine), 8.59(d, 1H, CH-pyridine), 7.36(dd, 1H, CH-pyridine), 7.85(dd, 1H, CH-pyridine). ^13^C NMR characteristic peaks appear at δ ppm: 134.7 (C~1~ of benzene), 128.2 (C~2,6~ of benzene), 128.8 (C~3~ and C~5~ of benzene), 131.0 (C~4~ of benzene), 157.2 (C~5~ of triazole), 151.1 (C~2~ of triazole), 164.6 (C~6~ of Triazine), 62.0 (C~5~ of Triazine),156.8 (C~4~ and C~6~ of pyrimidine), 119 (pyrimidine C-Cl), 155 (C~2~ pyridine, C-N), 124.2 (C~3~ pyridine), 137.2 (C~4~ pyridine), 123.6 (C~5~ pyridine), 149.2 (C~6~ pyridine).For compound (6b) (8-(5-chloropyrimidin-2-yl)-6-phenyl-3-(pyrimidin-4-yl)-7,8-dihydro\[1,2,4\]triazolo-\[4,3-b\] \[1,2,4\]triazine):Yield 41%, crystals from dioxan/diluted by methanol, mp 188--191 ^o^C. Analysis calculated for C~18~H~12~ClN~9~ (389): C, 55.46; H, 3.10; Cl, 9.10; N, 32.34. The analyses found for the compound are: C, 55.5; H, 3.08; N, 32.3; Cl, 9.2. IR characteristic peaks appear at (ν cm^−1^): 3078, 2959 cm^−1^ (aromatic & aliphatic (CH)), 1519 (C=N). ^1^H NMR characteristic peaks appear at δ ppm: 3.4(s, (2H), CH~2~, triazine ring), 8.08 (s, 2H, (CH)-pyrimidine), 7.52--7.94(m, 5H, CH-benzene), 8.29 (d, 1H, CH- pyrimidine), 9.36(s, 1H, CH- pyrimidine), 9.20(d, 1H, CH- pyrimidine). ^13^C NMR characteristic peaks appear at δ ppm: 134.0 (C~1~ of benzene), 128.2 (C~2,6~ of benzene), 128.8 (C~3~ and C~5~ of benzene), 131.0 (C~4~ of benzene), 157.2 (C~5~ of triazole), 151.1 (C~2~ of triazole), 164.6 (C~6~ of triazine), 62.0 (C~5~ of triazine),156.8 (C~4~ and C~6~ of pyrimidine), 119 (pyrimidine C-Cl), 167.9 (C~2~ pyrimidine, C-N), 164 (C~4~ non-substituted pyrimidine), 115.6 (C~5~ of non-substituted pyrimidine), 157.1 (C~6~ of non-substituted pyrimidine).For compound (6c) (8-(5-bromopyrimidin-2-yl)-6-phenyl-3-(pyridin-2-yl)-7,8-dihydro-\[1,2,4\]triazolo-\[4,3-b\] \[1,2,4\]triazine):Yield 36%, crystals from dioxan/diluted by methanol, mp 157--160 ^o^C. Analysis calculated for C~19~H~13~BrN~8~ (432): C, 52.67; H, 3.02; Br, 18.44; N, 25.86. The analyses found for the compound are: C, 52.7; H, 3.01; N, 25.9; Br, 18.5. IR characteristic peaks appear at (ν cm^−1^): 3089, 2977 cm^−1^ (aromatic & aliphatic (CH)), 1520 (C=N). ^1^H NMR characteristic peaks appear at δ ppm: 3.3 (s, (2H), CH~2~, triazine ring), 8.5 (s, 2H, (CH)-pyrimidine), 7.4--7.8 (m, 5H, CH-benzene), 8.8 (d, 1H, CH- pyridine), 8.9 (d, 1H, CH-pyridine), 7.6 (dd, 1H, CH-pyridine), 7.8 (dd, 1H, CH-pyridine). ^13^C NMR characteristic peaks appear at δ ppm: 134.0 (C~1~ of benzene), 128.2 (C~2,6~ of benzene), 128.8 (C~3~ and C~5~ of benzene), 131.0 (C~4~ of benzene), 157.2 (C~5~ of triazole), 151.1 (C~2~ of triazole), 164.6 (C~6~ of triazine), 62.0 (C~5~ of triazine),159.1 (C~4~ and C~6~ of pyrimidine), 110.7 (pyrimidine C-Br), 168.4 (C~2~ pyrimidine, C-N), 155 (C~2~ pyridine, C-N), 124.2 (C~3~ pyridine), 137.2 (C~4~ of pyridine), 123.5 (C~5~ of pyridine), 149.2 (C~6~ of pyridine).For compound (6d) (8-(5-bromopyrimidin-2-yl)-6-phenyl-3-(pyrimidin-4-yl)-7,8-dihydro-\[1,2,4\]triazolo-\[4,3-b\]\[1,2,4\]triazine):Yield 49%, crystals from dioxan/diluted by methanol, mp 189--191 ^o^C. Analysis calculated for C~18~H~12~BrN~9~ (433): C, 49.79; H, 2.79; Br, 18.40; N, 29.03. The analyses found for the compound are: C, 49.7; H, 2.8; N, 29.1; Br, 18.4. IR characteristic peaks appear at (ν cm^−1^): 3078, 2959 cm^−1^ (aromatic & aliphatic (CH)), 1522 (C=N). ^1^H NMR characteristic peaks appear at δ ppm: 3.5 (s, (2H), CH~2~, triazine ring), 8.4 (s, 2H, (CH)-pyrimidine), 7.5--7.9 (m, 5H, CH-benzene), 8.17 (d, 1H, CH- pyrimidine), 9.36(s, 1H, CH- pyrimidine), 9.20(d, 1H, CH- pyrimidine). ^13^C NMR characteristic peaks appear at δ ppm: 134.0 (C~1~ of benzene), 128.2 (C~2,6~ of benzene), 128.8 (C~3~ and C~5~ of benzene), 131.0 (C~4~ of benzene), 157.2 (C~5~ of triazole), 151.1 (C~2~ of triazole), 164.6 (C~6~ of triazine), 62.0 (C~5~ of triazine),159.1 (C~4~ and C~6~ of pyrimidine), 110.7 (pyrimidine C-Br), 168.4 (C~2~ pyrimidine, C-N), 167.9 (C~2~ pyrimidine, C-N), 164 (C~4~ pyrimidine, C-N), 115.5 (C~5~ of non-substituted pyrimidine), 157.1 (C~6~ of non-substituted pyrimidine).For compound (7a) (8-(5-chloropyrimidin-2-yl)-6-methyl-3-phenyl-\[1,2,4\]triazolo\[4,3-b\]\[1,2,4\]triazin-7(8H)-one):Yield 55% crystal from ethanol; mp 300--303 ^o^C. Analysis calculated for C~15~H~10~ClN~7~O (339): C, 53.03; H, 2.97; Cl, 10.44; N, 28.86. The analyses found for the compound are: C,53.02; H, 3.0; N, 28.9; Cl, 10.4. IR characteristic peaks appear at (ν cm^−1^): 3089, 2988 cm^−1^ (aromatic & aliphatic (CH)), 1725 (C=O), 1590 (C=N). ^1^H NMR characteristic peaks appear at δ ppm: 2.07(s, 3H, CH~3~), 8.05(s, 2H, (CH)-pyrimidine), 7.41--8.28(m, 5H, CH-benzene). MS (m/z, %): 339 (M+, 100.0%), 341 (M + 2, 32.4%), 225 (M + - 5-chloropyrimidine, 13.4%), 227 ((M + 2)-5-chloropyrimidine, 4.8%), 114 (5-chloropyrimidine, 32%), 116 (5-chloropyrimidine, 10.3%).For compound (7b) (8-(5-chloropyrimidin-2-yl)-6-methyl-3-(pyridin-4-yl)-\[1,2,4\]triazolo\[4,3-b\]\[1,2,4\]-triazin-7(8H)-one):Yield 39% crystal from ethanol; mp 289--292 ^o^C. Analysis calculated for C~14~H~9~ClN~8~O (340): C, 49.35; H, 2.66; Cl, 10.41; N, 32.89. The analyses found for the compound are: C,49.4; H, 2.7; N, 32.9; Cl, 10.4. IR characteristic peaks appear at (ν cm^−1^): 3091, 2979 cm^−1^ (aromatic & aliphatic (CH)), 1728 (C=O), 1522 (C=N). ^1^H NMR characteristic peaks appear at δ ppm: 2.18 (s, 3H, CH~3~), 8.02 (s, 2H, (CH)-pyrimidine), 7.99(d, (2H), (CH)-pyridine), 8.75(d, (2H), (CH)-pyridine). MS (m/z, %): 340 (M+, 100.0%), 342 (M^+^ + 2, 32.4%), 226 (M + - 5-chloropyrimidine, 12.3%), 228 ((M + 2) - 5-chloropyrimidine, 4.1%), 114 (5-chloropyrimidine, 15.3%), 116 (5-chloropyrimidine, 5.1%).For compound (7c) (8-(5-bromopyrimidin-2-yl)-6-methyl-3-(pyridin-4-yl)-\[1,2,4\]triazolo\[4,3-b\]\[1,2,4\]-triazin-7(8H)-one):Yield 42% crystal from ethanol; mp 244--246 ^o^C. Analysis calculated for C~15~H~10~BrN~7~O (383): C, 46.89; H, 2.62; Br, 20.80; N, 25.52. The analyses found for the compound are: C,47.0; H, 2.6; N, 25.5; Br, 20.8. IR characteristic peaks appear at (ν cm^−1^): 3077, 2987 cm^−1^ (aromatic & aliphatic (CH)), 1724 (C=O), 1520 (C=N). ^1^H NMR characteristic peaks appear at δ ppm: 2.23 (s, 3H, CH~3~), 8.78 (s, 2H, (CH)-pyrimidine), 7.41--8.22 (m, 5H, CH-benzene). MS (m/z, %): 383 (M^+^, 100.0%), 385 (M + 2, 33.4%), 225 (M^+^ - 5-bromopyrimidine, 9.6%), 227 ((M + 2) - 5-bromopyrimidine, 3.2%), 158 (5-bromopyrimidine, 21.3%), 160 (5-bromopyrimidine, 7.1%).For compound (7d) (8-(5-chloropyrimidin-2-yl)-3-phenyl-\[1,2,4\]triazolo\[4,3-b\]\[1,2,4\]triazine-6,7(5H,8H)-dione):Yield 36% crystal from ethanol; mp 274--276 ^o^C. Analysis calculated for C~14~H~9~BrN~8~O (384): C, 43.66; H, 2.36; Br, 20.74; N, 29.09. The analyses found for the compound are: C,43.7; H, 2.4; N, 29.1; Br, 20.7. IR characteristic peaks appear at (ν cm^−1^): 3079, 2977 cm^−1^ (aromatic & aliphatic (CH)), 1730 (C=O), 1518 (C=N). ^1^H NMR characteristic peaks appear at δ ppm: 2.17(s, 3H, CH~3~), 8.43(s, 2H, (CH)-pyrimidine), 7.95 (d, (2H), (CH)-pyridine), 8.78 (d, (2H), (CH)-pyridine). MS (m/z, %): 384 (M+, 100.0%), 386 (M + + 2, 33.2%), 226 (M + - 5-bromopyrimidine, 11.7%), 228 ((M + 2) - 5-bromopyrimidine, 3.8%), 159 (5-bromopyrimidine, 17.5%), 161 (5-bromopyrimidine, 5.8%).For compound (8a) (8-(5-chloropyrimidin-2-yl)-3-(pyridin-4-yl)-\[1,2,4\]triazolo\[4,3-b\]\[1,2,4\]triazine-6,7(5H,8H)-dione):Yield 42% crystalized from ethanol; mp 152--155 ^o^C. Analysis calculated for C~14~H~8~ClN~7~O~2~ (341): C, 49.21; H, 2.36; Cl, 10.38; N, 28.69. The analyses found for the compound are: C, 49.2; H, 2.4; N, 28.7, Cl, 10.4. IR characteristic peaks appear at (ν cm^−1^): 3233 (NH), 3079 (aromatic (CH)), 1734, 1658 (2C=O), 1522 (C=N). ^1^H NMR characteristic peaks appear at δ ppm: 7.6 (s, (1H), NH), 8.05 (s, 2H, (CH)-pyrimidine), 7.03--8.28 (m, 5H, CH-benzene).For compound (8b) (8-(5-bromopyrimidin-2-yl)-3-phenyl-\[1,2,4\]triazolo\[4,3-b\]\[1,2,4\]triazine-6,7(5H,8H)-dione):Yield 38% crystalized from ethanol; mp 215--217 ^o^C. Analysis calculated for C~13~H~7~ClN~8~O~2~ (342): C, 45.56; H, 2.06; Cl, 10.35; N, 32.70. The analyses found for the compound are: C, 45.6; H, 2.1; N, 32.7, Cl, 10.3. IR characteristic peaks appear at (ν cm^−1^): 3197 (NH), 1729, 1666 (C=O), 1520 (C=N). ^1^H NMR characteristic peaks appear at δ ppm: 7.9 (s, (1H), NH), 8.12 (s, 2H, (CH)-pyrimidine), 7.96 (d, (2H), (CH)-pyridine), 8.05 (d, (2H), (CH)-pyridine).For compound (8c) (8-(5-bromopyrimidin-2-yl)-3-phenyl-\[1,2,4\]triazolo\[4,3-b\]\[1,2,4\]triazine-6,7(5H,8H)-dione):Yield 52% crystalized from ethanol/acetic acid mixture; mp 197--199 ^o^C. Analysis calculated for C~14~H~8~BrN~7~O~2~ (384): C, 43.54; H, 2.09; Br, 20.69; N, 25.39. The analyses found for the compound are: C, 43.5; H, 2.1; N, 25.4, Br, 20.7. IR characteristic peaks appear at (ν cm^−1^): 3188 (NH), 3080 (aromatic (CH)), 1731, 1656 (C=O), 1519 (C=N). ^1^H NMR characteristic peaks appear at δ ppm: 7.81 (s, (1H), NH), 8.42 (s, 2H, (CH)-pyrimidine), 7.45--8.06 (m, 5H, CH-benzene).For compound (8d) (8-(5-bromopyrimidin-2-yl)-3-(pyridin-4-yl)-\[1,2,4\]triazolo\[4,3-b\]\[1,2,4\]triazine-6,7(5H,8H)-dione):Yield 57% crystalized from diluted ethanol; mp 223--225 ^o^C. Analysis calculated for C~13~H~7~BrN~8~O~2~ (385): C, 40.33; H, 1.82; Br, 20.64; N, 28.94. The analyses found for the compound are: C, 40.3; H, 1.8; N, 28.9, Br, 20.6. IR characteristic peaks appear at (ν cm^−1^): 3180 (NH), 3088 (aromatic (CH)), 1735, 1668 (C=O), 1520 (C=N). ^1^H NMR characteristic peaks appear at δ ppm: 7.82 (s, (1H), NH), 8.43 (s, 2H, (CH)-pyrimidine), 7.87 (d, (2H), (CH)-pyridine), 8.15 (d, (2H), (CH)-pyridine).For compound (9a) (3-hydrazinyl-5-phenyl-4H-1,2,4-triazol-4-amine):Yield 67% crystal from ethanol; mp 155--157 ^o^C. Analysis calculated for C~8~H~10~N~6~ (190): C, 50.52; H, 5.30; N, 44.18. The analyses found for the compound are: C, 50.5; H, 5.3; N, 44.2. UV \[DMF, λ ~max~ nm (Log ε)\]: 316 (2.4) nm. IR characteristic peaks appear at (ν cm^−1^): 3344, (NH~2~), 3174 (NH), 3076 (aromatic (CH)), 1602 (deformation NH~2~), 1522 (C=N). ^1^H NMR characteristic peaks appear at δ ppm: 4.11 (s, (2H), NH~2~ of hydrazine), 5.77 (s, (2H), NH~2~ of triazole), 7.41--8.08 (m, 5H, CH-benzene), 9.23 (s, 1H, NH of hydrazine).For compound (9b)(3-hydrazinyl-5-(pyridin-4-yl)-4H-1,2,4-triazol-4-amine):Yield 58% crystal from ethanol; mp 187--189 ^o^C. Analysis calculated for C~7~H~9~N~7~ (191): C, 43.97; H, 4.74; N, 51.28. The analyses found for the compound are: C, 44.0; H, 4.7; N, 51.3. UV \[DMF, λ ~max~ nm (Log ε)\]: 312 (2.1) nm. IR characteristic peaks appear at (ν cm^−1^): 3356, (NH~2~), 3181 (NH), 1600 (deformation NH~2~), 1518 (C=N). ^1^H NMR characteristic peaks appear at δ ppm: 4.23 (s, (2H), NH~2~ of hydrazine), 5.53 (s, (2H), NH~2~ of triazole), 7.83 (d, (2H), (CH)-pyridine), 8.87 (d, (2H), (CH)-pyridine), 9.76 (s, (1H), NH).For compound (10a) (7-phenyl-3,4-dihydro-\[1,2,4\]triazolo\[4,3-e\]\[1--5\] tetrazaphosphinine):Yield 58% crystal from THF; mp 267--269 ^o^C. Analysis calculated for C~8~H~7~N~6~P (218): C, 44.04; H, 3.23; N, 38.52; P, 14.20. The analyses found for the compound are: C, 44.0; H, 3.3; N, 38.50; P, 14.2. IR characteristic peaks appear at (ν cm^−1^): 3123--2962 (broad, NH-NH), 1650 (P-NH), 1528 (C=N); ^1^H NMR characteristic peaks appear at δ ppm: 4.25 (s, 1H, NH-N), 6.32 (s, 1H, NH-P), 7.41--8.28 (m, 5H, CH-benzene). MS (m/z, %): 218 (M + ,4.34%), 194 (M^+^ - NH-NH, 100%), 163 (M^+^ - NH-NH-P, 44%), 148 (M^+^ - NH-NH-P-N, 2.21%).For compound (10b) (7-(pyridin-4-yl)-3,4-dihydro-\[1,2,4\]triazolo\[4,3-e\]\[1--5\] tetrazaphosphinine):Yield 44% crystal from THF; mp 226--228 ^o^C. Analysis calculated for C~7~H~6~N~7~P (219): C, 38.37; H, 2.76; N, 44.74; P, 14.13. The analyses found for the compound are: C, 38.4; H, 2.8; N, 44.8; P, 14.1. IR characteristic peaks appear at (ν cm^−1^): 3120--2965 (broad, NH-NH), 1643 (P-NH), 1522 (C=N). ^1^H NMR characteristic peaks appear at δ ppm: 4.31 (s, 1H, NH-N), 6.52 (s, 1H, NH-P), 7.94 (d, (2H), (CH)-pyridine), 8.79 (d, (2H), (CH)-pyridine). MS (m/z, %): 219 (M^+^,6.22%), 195 (M^+^ - NH-NH, 100%), 164 (M^+^ - NH-NH-P, 37%), 149 (M^+^ - NH-NH-P-N, 5.11%).For compound (11a) (3-phenyl-1,7-dihydro-\[1,2,4\]triazolo\[4,3-b\]\[1,2,4,5\]tetrazine):Yield 37% crystallized from dioxane; mp 252--254 ^o^C. Analysis calculated for C~9~H~8~N~6~ (200): C, 53.99; H, 4.03; N, 41.98. The analyses found for the compound are: C, 54.0; H, 4.0; N, 42.0. IR characteristic peaks appear at (ν cm^−1^): 3184,3132 (NH, NH of tetrazine and triazole), 1521 (C=N). ^1^H NMR characteristic peaks appear at δ ppm: 3.41 (s, 1H, NH-tetrazine), 5.82 (s, br., 1H, NH-triazole), 7.02 (s, 1H, CH-tetrazine), 7.51--7.82 (m, 5H, CH-benzene).For compound (11b) (3-(pyridin-4-yl)-1,7-dihydro-\[1,2,4\]triazolo\[4,3-b\]\[1,2,4,5\]tetrazine):Yield 41% crystallized from dioxan; mp 271--273 ^o^C. Analysis calculated for C~8~H~7~N~7~ (201): C, 47.76; H, 3.51; N, 48.73. The analyses found for the compound are: C, 47.7; H, 3.5; N, 48.7. IR characteristic peaks appear at (ν cm^−1^): 3188, 3129 (NH, NH of tetrazine and triazole), 1519 (C=N). ^1^H NMR characteristic peaks appear at δ ppm: 3.62 (s, br., 1H, NH-tetrazine), 6.21 (s, br., 1H, NH-triazole), 7.36 (s, 1H, CH-tetrazine), 7.90 (d, (2H), (CH)-pyridine), 8.63 (d, (2H), (CH)-pyridine).For compound (12a) (6-(2-chloro-6-fluorophenyl)-3-phenyl-5,6,7,8-tetrahydro-\[1,2,4\]triazolo\[4,3-b\]\[1,2,4,5\]tetrazine):Yield 53% crystal from dioxan; mp 234--236 ^o^C. Analysis calculated for C~15~H~12~ClFN~6~ (330): C, 54.47; H, 3.66; Cl, 10.72; F, 5.74; N, 25.41. The analyses found for the compound are: C, 54.5; H, 3.7; N, 25.4; F, 5.7; Cl, 10.7. UV \[DMF, λ ~max~ nm (Log ε)\]: 265 (1.13) and 263 (1.03) nm. IR characteristic peaks appear at (ν cm^−1^): 3354,3169 and 3132 cm^−1^ (3NH), 3078 (aromatic (CH)), 1522 cm^−1^ (C=N). ^1^H NMR characteristic peaks appear at δ ppm: 2.31 (s, 1H, NH-tetrazine at 2-position), 4.32 (s, 1H, NH-tetrazine at 4-position), 5.04 (s, 1H, CH-tetrazine), 6.32 (s, 1H, NH-tetrazine at 5-position), 7.07--8.28 (m, 8H, CH-aromatic). ^13^C NMR characteristic peaks appear at δ ppm: 157.2 (C~3~ of triazole), 151.1 (C~5~ of triazole), 130.6 (C~1~ of non-substituted benzene), 127.5 (C~2~, C~6~ of non-substituted benzene), 129.2 (C~3~, C~5~ of non-substituted benzene), 131.1 (C~4~ of non-substituted benzene), 73.5 (C~3~ of tetrazine), 133.8 (C-Cl), 160.8 (C-F), 129.8 (C~2~ of substituted benzene), 124.2, 129.7, 113.4 (3 C of substituted benzene).For compound (12b) (6-(2-chloro-6-fluorophenyl)-3-(pyridin-4-yl)-5,6,7,8-tetrahydro-\[1,2,4\]triazolo\[4,3-b\]\[1,2,4,5\] tetrazine):Yield 46% crystal from dioxan; mp 256--258 ^o^C. Analysis calculated for C~14~H~11~ClFN~7~ (331): C, 50.69; H, 3.34; Cl, 10.69; F, 5.73; N, 29.56. The analyses found for the compound are: C, 50.7; H, 3.4; N, 29.5; F, 5.7; Cl, 10.6. UV \[DMF, λ ~max~ nm (Log ε)\]: 263(1.11) and 261 (1.01) nm. IR characteristic peaks appear at (ν cm^−1^): 3343, 3154 and 3129 cm^−1^ (3NH), 3072 (aromatic (CH)), 1518 cm^−1^ (C=N). ^1^H NMR characteristic peaks appear at δ ppm: 2.42 (s, 1H, NH-tetrazine at 2-position), 4.51 (s, 1H, NH-tetrazine at 4-position), 5.32 (s, 1H, CH-tetrazine), 6.50 (s, 1H, NH-tetrazine at 5-position), 7.01--7.32 (m, 3H, CH-aromatic), 7.92 (d, (2H), (CH)-pyridine), 8.71 (d, (2H), (CH)-pyridine). ^13^C NMR characteristic peaks appear at δ ppm: 157.2 (C~3~ of triazole), 151.1 (C~5~ of triazole), 134.0 (C4 of pyridine), 121.3 (C~3~, C~5~ of pyridine), 149.8 (C~2~, C~6~ of pyridine), 73.5 (C~3~ of tetrazine), 133.8 (C-Cl), 160.8 (C-F), 129.8 (C~2~ of substituted benzene), 124.2, 129.7, 113.4 (3C of substituted benzene).For compound (13a) (3-phenyl-7,8-dihydro-\[1,2,4\]triazolo\[4,3-b\]\[1,2,4,5\]tetrazine-6(5H)-thione):Yield 45% crystal from THF; mp 276--278 ^o^C. Analysis calculated for C~9~H~8~N~6~S (232): C, 46.54; H, 3.47; N, 36.18; S, 13.81. The analyses found for the compound are: C, 46.5; H, 3.5; N, 36.2; S, 13.8. UV \[λ~max~ (Log ε)\]: 314 (2.1) nm. IR characteristic peaks appear at (ν cm^−1^): 3332, 3178 (NH-NH), 1528 (C=S). ^1^H NMR characteristic peaks appear at δ ppm: 3.8 (s, br., 1H, -NH- tetrazine at position 2), 5.3 (s, br., 1H, NH-tetrazine at position 4), 6.1 (s, br., 1H, NH-tetrazine at position 5), 7.52--8.07 (m, 5H of benzene). ^13^C NMR characteristic peaks appear at δ ppm: 157.2 (C~3~ of triazole), 151.1 (C~5~ of triazole), 182.1 (C~3~ of tetrazine), 130.6 (C~1~ of benzene), 127.5 (C~2,6~ benzene), 129 (C~3,5~ of benzene), 131.1 (C~4~ of benzene).For compound (13b) (3-(pyridin-4-yl)-7,8-dihydro-\[1,2,4\]triazolo\[4,3-b\]\[1,2,4,5\]tetrazine-6(5H)-thione):Yield 51% crystal from THF; mp 255--258 ^o^C. Analysis calculated for C~8~H~7~N~7~S (233): C, 41.19; H, 3.02; N, 42.03; S, 13.75. The analyses found for the compound are: C, 41.2; H, 3.0; N, 42.0; S, 13.8. UV \[λ~max~ (Log ε)\]: 312 (1.8) nm. IR characteristic peaks appear at (ν cm^−1^): 3325, 3182 (NH-NH), 1522 (C=S). ^1^H NMR characteristic peaks appear at δ ppm: 3.2 (s, br., 1H, -NH- tetrazine at position 2), 5.1 (s, br., 1H, NH-tetrazine at position 4), 5.9 (s, br., 1H, NH-tetrazine at position 5), 7.99 (d, 2H of pridine at C~3~, C~5~), 8.77 (d, 2H of pyridine at C~2~, C~6~). ^13^C NMR characteristic peaks appear at δ ppm: 157.2 (C~3~ of triazole), 151.1 (C~5~ of triazole), 182.1 (C~3~ of tetrazine), 134.0 (C~4~ of pyridine), 149.8 (C~2,6~ of pyridine), 121.3 (C~3,5~ of pyridine).For compound (14a) (3-phenyl-7,8-dihydro-\[1,2,4\]triazolo\[4,3-b\]\[1,2,4,5\]tetrazin-6(5H)-one):Yield 43% crystal from ethanol; mp 191--193 ^o^C. Analysis calculated for C~9~H~8~N~6~O (216): C, 50.00; H, 3.73; N, 38.87. The analyses found for the compound are: C, 50.1; H, 3.7; N, 38; 9. UV \[λ ~max~ (Log ε)\]: 324 (1.51) nm. IR characteristic peaks appear at (ν cm^−1^): 3167 (NH-NH), 1643 (amidic CO), 1563 (C=N); ^1^H NMR characteristic peaks appear at δ ppm: 2.9 (s, br., 1H, NH- tetrazine at position 2), 4.8 (s, br., 1H, NH-tetrazine at position 4), 5.6 (s, br., 1H, NH-tetrazine at position 5), 7.87--8.08 (m, 5H of benzene). ^13^C NMR characteristic peaks appear at δ ppm: 157.2 (C~3~ of triazole), 151.1 (C~5~ of triazole), 152.4 (C~3~ of tetrazine), 130.6 (C~1~ of benzene), 127.5 (C~2,6~ of benzene), 129.2 (C~3,5~ of benzene), 131.1 (C4 of benzene). MS (m/z, %): 216 (M^+^, 4.7%), 188 (M^+^ - CO, 100%), 173 (M^+^ - CO-NH, 4.3%).For compound (14b) (3-(pyridin-4-yl)-7,8-dihydro-\[1,2,4\]triazolo\[4,3-b\]\[1,2,4,5\]tetrazin-6(5H)-one):

Yield 38% crystal from ethanol; mp 170--173 ^o^C. Analysis calculated for C~8~H~7~N~7~O (217): C, 44.24; H, 3.25; N, 45.14. The analyses found for the compound are: C, 44.2; H, 3.3; N, 45.1. UV \[λ ~max~ (Log ε)\]: 320 (1.21) nm. IR characteristic peaks appear at (ν cm^−1^): 3172 (NH-NH), 1651 (amidic CO), 1534 (C=N). ^1^H NMR characteristic peaks appear at δ ppm: 3.1 (s, br., 1H, -NH- tetrazine at position 2), 5.1 (s, br., 1H, NH-tetrazine at position 4), 5.9 (s, br., 1H, NH-tetrazine at position 5), 7.98 (d, 2H of pyridine at C~2,6~), 8.67 (d, 2H, of pyridine at C~3,5~). ^13^C NMR characteristic peaks appear at δ ppm: 157.2 (C~3~ of triazole), 151.1 (C~5~ of triazole), 152.4 (C~3~ of tetrazine), 134.0 (C~4~ of pyridine), 149.8 (C~2,6~ of pyridine), 121.3 (C~3,5~ of pyridine). MS (m/z, %): 217 (M^+^, 6.2%), 189 (M^+^ - CO, 100%), 174 (M^+^ - CO-NH, 3.7%).

Samples characterization {#Sec15}
------------------------

From the above mentioned spectral data and physical constants of the newly synthesized compounds, we concluded that: the mercapto group in the 4-amino-5-phenyl-4H-1,2,4-triazole-3-thiol (**1a**) is simply displaced by the amino group (nucleophilic group) in heterocyclic primary amines such as 5-chloropyrimidin-2-amine (**2a**) in Ethanol-DMF mixture (1:1) under reflux to yield 4-amino-5-substituted amino-1,2,4-triazole derivative (**3a**). Structure of **3a** was elucidated mainly from the disappearance of the mercapto group peak at 2600--2500 cm^−1^ in the IR spectrum, the new NH proton with NH~2~ proton of aminotriazole of compound **3a** showed through the ^1^H NMR spectrum at δ 14.22 ppm 5.87 ppm respectively. Also, the UV absorption of **3a** shows λ ~max~ at 372 nm while the λ ~max~ of **1a** appears at 317 nm, which proves the structure of compound **3a** (Fig. [1](#Fig1){ref-type="fig"}). Ring closure reactions^[@CR39]^ of compound **3a** with diphenyl(chloromethyl)-phosphanoxide **(4)** under reflux in tetrahydrofuran (THF) produces 3,8-diaryl-4,5,6,7-tetrahydro-6-hydroxy-1,2,4-triazole\[4,3-*b*\]\[1--3,5\]-phosphotriazine (**5a**) (Fig. [1](#Fig1){ref-type="fig"}). The presence of C-H, P-OH, P-N and NH, P-N, P-OH, and C-H functional groups peaks at 1522, 1650, 2925 and 3080 cm^−1^ in its IR spectrum were used to deduce the structure of **5a**. This structure was confirmed also by ^1^H NMR spectrum which showed resonated signals at δ 2.8 (s, 1H, OH), 3.1 (s, (2H), CH~2~), 2.0 (s, 1H, N-H), 7.41--8.05 (m, 15H, CH-benzene) and 8.08 (s, 2H, (CH)-pyrimidine).Figure 1Synthesis of triazolotriazine derivatives **5--8**.

Derivatives of 1,2,4-Triazolo\[4,3-*b*\]-1,2,4-triazine compounds (**6a--8a**) have been obtained from the hetero-cyclization of compound **3a** with phenacyl bromide dissolved in ethanolic potassium hydroxide, pyruvic acid dissolved sodium hydroxide and diethyloxalate dissolved in DMF/THF under reflux, respectively (Fig. [1](#Fig1){ref-type="fig"}). The chemical structures of compounds **6a--8a** were elucidated from both the spectral measurements and the elemental analyses. Infrared spectrum analysis of compound **6a** showed representative bands at ν 3079 (cm^−1^) and 2966 (cm^−1^) for aromatic & aliphatic (CH) and band at 1522 for (C=N). While, representing bands of compound **7a** were recorded at ν = 2978 (cm^−1^), 1480 (cm^−1^) for (stretching and bending vibration of CH~3~) and a band at 1725(cm^−1^) for (C=O). In addition to that compound **8a** bands were recorded at ν 3233 (cm^−1^) for NH, 1734(cm^−1^) and 1658(cm^−1^) for (2C=O), C=N and substituted pyrimidine and aromatic rings bands appear at 1522(cm^−1^) and 850--730 (cm^−1^). Also, 4 amino-5-(4 pyridyl)-4 *H*-1,2,4-triazole-3-thiol compound (**1b**) reacted with 5-chloro-pyrimidine-2-amine **(2b)** in Ethanol/DMF mixture (1:1) under reflux to give 4-amino-5-substituted amino-1,2,4-triazole derivative **3b. Compound 3b** in turn, undergo ring closure with each of diphenyl (chloromethyl) - phosphanoxide **(4)** in THF/TEA, phenacyl bromide in ethanolic KOH, pyruvic acid in NaOH, and/or diethyloxalate in THF/DMF to provide the compounds **5b to 8b**, respectively. The chemical structures of compounds **5b-8b** were confirmed by considering both spectral measurements and elemental analyses. In a similar way, under the same above-mentioned experimental conditions, the reaction of compound **1a,b** with 5-bromopyrimidin-2-amine **(2c)** takes place to give **3c,d** compounds respectively. The triazole-3,4-diamines **3c,d** were cyclized with each of diphenyl(choro-methyl)phosphanoxide **(4)**, phenacyl bromide, pyruvic acid, and diethyloxalate to give the corresponding compounds **5c,d--8c,d**, respectively, The chemical structures of compounds**5c,d--8c,d** were elucidated by their spectral measurements and elemental analyses data.

The reported results of the high potency of 1,2,4-triazolo\[1,2,4,5\]tetrazines system as antimicrobial and anti-inflammatory agents were our motivation to synthesize several derivatives of these rings. Thus, it was found that refluxing compound **1a,b** with hydrazine hydrate dissolved in ethanol gives the corresponding 5 hydrazine-4-amino-1,2,4-triazoles (**9a,b**) which was used as new synthons for the present study aiming to build new 1,2,4-triazolotetrazines. A hydrazino group is a stronger nucleophilic group and more basic if it is compared to the amino group in both compounds **9a**,**b**, which enhances the cyclization firstly followed by the amino center (Fig. [2](#Fig2){ref-type="fig"}). The triazolo\[4,3-*e*\]\[1--5\] tetrazaphosphinines (**10a,b**) were obtained from refluxing **9a**,**b** with triethylphosphite in tetrahydrofuran (THF), respectively. Treating compound **9a,b** with triethylorthoformate under the previously mentioned conditions, produced the corresponding 3-(pyridin-4-yl)- and/or 3-phenyl-1,7-dihydro-\[1,2,4\]triazolo\[4,3-*b*\]\[1,2,4,5\]-tetrazine **11a** and/or **11b**, respectively. Cycloaddition reaction, in boiling ethanol with a few drops of piperidine, of compounds **9a,b** with 2-chloro--6-fluorobenzeldehyde furnished the corresponding triazolotetrazine derivatives **12 a,b**, respectively **(**Fig. [2](#Fig2){ref-type="fig"}).Figure 2Synthesis of triazolotetrazine derivatives 1**0--14**.

Structures of compounds **10a,b, 11a,b** and **12a,b** were elucidated by examining the data of IR spectra. The IR absorption bands at ν (cm^−1^): 3123--2962, 3120--2965 of (broad NH-NH), 1650, 1643 of (P-NH), 1528, 1522 of (C=N) for **10a, b**, respectively. The IR absorption bands at ν (cm^-1^): 3184--3132, 3188--3129 of (NH, NH of tetrazine and triazole), 1521, 1519 (C=N) for **11a,b**, respectively. The IR absorption bands at ν (cm^−1^): 3354--3132, 3343--3129 (3NH), 3078, 3072 (aromatic (CH)), 1522, 1518 (C=N) for **12a,b**, respectively. The mass spectra of each of **10a** and **10b** gave molecular ion peaks at 218 and 219 which corresponded to the molecular weights of C~8~H~7~N~6~P and C~7~H~6~N~7~P of the assigned structures **10a**,**b**, respectively.

UV spectral data of both compounds **3a,b** and **12a,b** explains that the hetero-cyclization would inhibit the electronic transition and this caused the hypsochromic effect "shift to the shorter wavelength". Thus, λ~max~ of **3a,b** was 372 and 374 nm while that of **12a,b** was 265 and 263 nm, respectively. ^13^C NMR (DMSO) of compound **12a** showed the presence of thirteen different signals for thirteen different carbon atoms, which, for **12b**, showed twelve signals for twelve different carbons. Finally, the compounds 1,2,4-trizolo\[4,3 -b\]\[1,2,4,5\]tetrazine-5(4 *H*)-thiones/ones (**13a,b** and **14a,b**) were synthesized from refluxing of **9a,b** with CS~2~ in DMF and/or with ethyl chloroformate in THF/TEA, respectively (Fig. [2](#Fig2){ref-type="fig"}). Formation of **13a,b** occurs in two steps, the first, by addition to S=C=S and the second step is the elimination of H~2~S, while the formation of compounds **14a,b** was carried via esterification of **9a,b** followed by elimination of one molecule of ethanol in each case^[@CR52]^. The chemical structures of **13a,b**, and **14a,b** were characterized by their elemental and spectral analyses. Thus, the infrared spectra of compounds **14a,b** showed absorption bands of NH, CONH at ν 3167, 3172 and 1643, 1651cm^−1^, respectively, while that of **13a,b** showed the absorption bands at ν 3332, 3325 cm^−1^ of NH and 1528, 1522 cm^−1^ of (C=S). The ^1^H NMR spectra of **13a,b** recorded signals of 3.8 (s, 1H, -NH- tetrazine at position 2), 5.3 (s, 1H, NH-tetrazine at position 4), 6.1 (s, 1H, NH-tetrazine at position 5) and 7.52--8.07 (m, 5H of benzene). ^13^C NMR gives us good evidence for the structure of **13a** where it showed resonated signals at 157 (C~3~ -triazole), 151 (C~5~ -triazole), 182 (C~3~ -tetrazine) and 130, 131,129, 127 ppm of benzene carbons. Mass spectra of both compounds **14a**,**14b** showed molecular ion peaks at 216 (4.7%) for **14a** and at 217 (6.2%) for **14b**, which confirmed their structures. In addition, ^13^C NMR data of **14a** and **14b** gave convincing evidence to their structures in which compound **14a** revealed the presence of seven different carbon signals, while **14b** showed six different carbon signals, which were in good agreement with the proposed structures (Fig. [2](#Fig2){ref-type="fig"}).

### Biological activity {#Sec16}

The different biological activities of the synthesized compounds have been evaluated by studying their antibacterial activity against *Pseudomonas aeruginosa* and *Escherichia coli* as examples for Gram-negative bacteria *and Staphylococcus aureus* as an example for Gram-positive bacteria, in addition, the antifungal activity against *Candida albican*s using the technique reported by Barry *et al*.^[@CR53],[@CR54]^. Dimethylformamide was used as a solvent. Nystatin was used as a reference drug for fungi while Nalidixic acid and Imipenem were used as reference drugs for bacteria. The diameter of the growth inhibition zone (DIZ) was presented in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"} and Figs. [3](#Fig3){ref-type="fig"}--[6](#Fig6){ref-type="fig"}. The Minimum Inhibitory Concentrations (MIC) in antibacterial activity were presented in Table [1](#Tab1){ref-type="table"}.Table 1The antibacterial activity for some of the newly prepared Compounds.*[S. aureus]{.ul}[P.aeruginosa]{.ul}[E. coli]{.ul}*BacteriaMIC2550100MIC2550100MIC2550100Inhibitory\
ConcentrationsGrowth inhibition Zone (mm)^\*^Compounds75.7------2149.6---82838.6---17285a48.5---92368------2644.3---15315b49.6---52049.7---83332---20295c48.9---81846.9---113031.7---22325d68.2------1947.9---102238.3---15248a67.2------2479.6------2037.3---17278b46.9---102243.3---111926.6---19248c48.4---92479.5------1744.6---14298d68.7------2149---62542.6---15289a46.6---112561.3------2244.5---13269b75.1------2375.4------2145.5---132810a49.5---72245---102045.7---122510b66.5------2243.8---91425.7---142911a48.2---81940.4---111743.8---163211b75.3------1444.4---112044.6---142912a39.5---101553.5------2538.7---162612b61.7------1949.3---82330.3---162213a37.2---111649---92645.2---132713b73.6------1347.7---102544.5---122414a31.6---101349.6---82843.7---142714b23.36263145.3---1020------------Nalidixic acid14.217202615.914192313.9182228ImipenemTable 2The antifungal activity for some of the newly prepared Compounds.*[C. albicans]{.ul}*Fungi2550100Inhibitory ConcentrationsGrowth inhibition Zone (mm)^\*^Compounds------145a------175b------165c------145d------138a------148b------168c------148d------129a------119b------1310a------1210b------1211a------1411b------1212a------1012b------1113a------1313b------1214a------1114b------40Nystatin• Synthesized compounds (Inhibitor) Concentrations: 100, 50 and 25 μg /mL.Highly active: DIZ ≥ 12.Moderately active: DIZ = 9--12.Slightly active: DIZ = 6--9;Not sensitive: DIZ \< 6 mm.Figure 3The antibacterial activity comparison of some tested compounds with Nalidixic acid and Imipenem toward *E. coli* at different concentrations where: (**A**) 25 µg/mL (**B**) 50 µg/mL (**C**) 100 µg/mL.Figure 4The antibacterial activity comparison of some tested compounds with Nalidixic acid and Imipenem toward *P.aeruginosa* at different concentrations where: (**A**) 25 µg/mL (**B**) 50 µg/mL (**C**) 100 µg/mL.Figure 5The antibacterial activity comparison of some tested compounds with Nalidixic acid and Imipenem toward *S. aureus* at different concentrations where: (**A**) 25 µg/mL (**B**) 50 µg/mL (**C**) 100 µg/mL.Figure 6The antifungal activity comparison of some tested compounds with Nystatin toward *C. albicans* at different concentrations where: (**A**) 25 µg/mL (**B**) 50 µg/mL (**C**) 100 µg/mL.

The results in Table [1](#Tab1){ref-type="table"} show that the antibacterial activity of the tested compounds could be classified to higher to moderate activity against the used bacteria *E.coli, S. aureus and P. aeruginosa* in comparison with Nalidixic acid at concentrations 100, 50 and 25 µg/mL. All the tested Compounds showed higher activity against *E. coli* bacteria at 100 µg/mL concentrations and higher to moderate activity at 50 µg/mL concentrations. For *S. aureus* bacteria, all the tested Compounds showed higher activity at 100 µg/mL concentrations. Compounds **5a, 5c, 8a, 8b, 9a, 10a, 11a, 12a, 13a** and **14a** were not sensitive toward *S. aureus* while compounds **5d, 10b** and **11b** were slightly active at 50 µg/mL concentrations. On the other hand, the remaining compounds showed moderate activity at 50 µg/mL concentrations. For *P. aeruginosa* bacteria, all the tested compounds showed higher activity at 100 µg/mL concentrations. Compounds **5b, 8b, 8d, 9b, 10a** and **12b** were not sensitive toward *P. aeruginosa* bacteria while compounds **5a, 5c, 9a, 13a** and **14b** were slightly active at 50 µg/mL concentrations. On the other hand, the remaining compounds showed moderate activity at 50 µg/mL concentrations. The MICs for all the tested compounds against *E.coli, S. aureus, and P. aeruginosa* were presented in Table [1](#Tab1){ref-type="table"}. The data in Table [2](#Tab2){ref-type="table"} showed moderate to high antifungal activities of the tested compounds against *C. albicans* in comparison with Nystatin at 100 µg/mL concentration The MIC for all the tested compounds against *C. albicans* fungi was 100 µg/mL. The higher activity of some of the tested compounds was mainly due to containing chlorine, fluorine, bromine and phosphorus elements within the chemical structure of 1,2,4-triazine and 1,2,4,5-tetrazine^[@CR55]^. On the other hand, the obtained results in Table [3](#Tab3){ref-type="table"} indicated that: Compounds **10a,b, 12a,b** and **13b** carrying phenyl and pyridine groups having both the chlorine and fluorine elements had good anti-inflammatory activity, in comparison with the standard anti-inflammatory drug used (Indomethacin). Compounds **10a,b**, and **12a,b** contained mainly triazole and tetrazine rings with the presence of both fluorine and phosphorus elements, incorporated with pyridyl moiety. The activity of the new materials depends on the existence of those new moieties which have a high biological activity^[@CR55]^. The higher biological activity of the synthesized compounds was in a good agreement with the previously stated results in the field of fluorine and phosphorus-bearing nitrogen heterocyclic systems^[@CR9],[@CR56]^.Table 3The anti-inflammatory activity for some of the newly synthesized compounds.CompoundDose (mg /Kg)Paw edema(g)\* ± S.E.% inhibition9a2550.57 ± 0.050.61 ± 0.0613.637.579b2550.52 ± 0.050.59 ± 0.0621.2110.6010a2550.42 ± 0.050.48 ± 0.0636.3627.2710b2550.45 ± 0.050.49 ± 0.0631.8125.7512a2550.41 ± 0.030.48 ± 0.0637.8727.2712b2550.43 ± 0.050.47 ± 0.0634.8428.7813a2550.55 ± 0.050.64 ± 0.0516.663.0313b2550.40 ± 0.050.46 ± 0.0639.3930.30Control00.66 ± 0.050Indomethacin50.32 ± 0.0251.51^\*^Significant difference from the control value at p \< 0.05.

#### Molecular modeling studies (Structure-based drug design) {#FPar6}

Table [4](#Tab4){ref-type="table"} and Fig. [7](#Fig7){ref-type="fig"} illustrate the results of the bonding interactions for the docking of compound **5d** and **Nalidixic acid** with amino acids of DNA Gyrase enzyme (PDB ID: 2XCT) active site. From these results, we found that the active compound **5d** showed extra binding modes to DA13 and Arg 458 in addition to interaction with the essential binding sites Mn metal and DG5.Table 4Molecular modeling results for compound 5d and Nalidixic acid during docking in DNA Gyrase enzyme (PDB ID: 2XCT) active site.CompoundCOX-2 (PDB: 2XCT)Affinity\
Kcal/molDistance (in Å) from\
main residueFunctional\
groupInteraction2d caption(3d caption)**5d**−14.25891.623.954.763.933.73MnArg458 DG5DA13DA13Pyridine NDiazine ringPhenyl ringTriazole ringTriazole ringMetal Bondpi-Hpi-Hpi-pipi-piFig. [7a](#Fig7){ref-type="fig"}(Fig. [7b](#Fig7){ref-type="fig"})Nalidixic acid−10.06991.713.993.67MnDG5DG5Carbonyl groupPhenyl ringPhenyl ringMetal Bondpi-pipi-piFig. [7c](#Fig7){ref-type="fig"}(Fig. [7d](#Fig7){ref-type="fig"})Figure 7Molecular docked model of compound **5d** and **Nalidixic acid** with DNA Gyrase enzyme (the target is presented as thin sticks; the ligands are drawn as ball-and-stick). Images (**a,c**) represent the 2D docking styles for DNA Gyrase enzyme with compound **5d** and **Nalidixic acid**, respectively. Images (**b,d**) represent the 3D docking styles for compound **5d** and **Nalidixic acid**, respectively.

Table [5](#Tab5){ref-type="table"} and Fig. [8](#Fig8){ref-type="fig"} illustrate the results and the bonding interactions of the docked compounds and **Indomethacin**, respectively, with active sites of COX-2 (PDB ID: 1CX2).Table 5Molecular modeling results for compounds and Indomethacin during docking in COX-2 (PDB ID: 1CX2) active site.CompoundCOX-2 (PDB: 1CX2)Affinity\
Kcal/molDistance (in Å) from\
main residueFunctional\
groupInteraction2d caption\
(3d caption)10a−17.87104.47Arg513Triazole ringpi-cationFig. [8a](#Fig8){ref-type="fig"}(Fig. [8b](#Fig8){ref-type="fig"})10b−16.19902.473.71Tyr355Ser353Triazole NPyridine ringH-acceptorpi-HFig. [8c](#Fig8){ref-type="fig"}(Fig. [8d](#Fig8){ref-type="fig"})12a−15.38103.233.803.56Leu352Val523His90-NH-Phenyl ringTriazole ringH-donorpi-Hpi-piFig. [8e](#Fig8){ref-type="fig"}(Fig. [8f](#Fig8){ref-type="fig"})12b−16.20583.863.37Tyr355Ala527-NH-Triazole ringH-acceptor pi-HFig. [8g](#Fig8){ref-type="fig"}(Fig. [8h](#Fig8){ref-type="fig"})Indomethacin−15.87962.70Arg513CarbonylH-acceptorFig. [8i](#Fig8){ref-type="fig"}(Fig. [8j](#Fig8){ref-type="fig"})Figure 8Molecular docked model of compounds **10a,b, 12a,b** and Indomethacin with COX--II enzyme (the target is presented as thin sticks; the ligands are drawn as ball-and-stick). Images (**a,c,e,g,i**) represent the 2D docking styles for COX--II enzyme with compounds **10a,b, 12a,b** and Indomethacin, respectively. Images (**b,d,f,h,j**) represent the 3D docking styles for COX--II enzyme with compounds **10a,b, 12a,b** and Indomethacin, respectively.

From these results, it appears that, generally, the tested compounds and Indomethacin showed a comparable binding pattern. Compound **10a** showed well interaction with Arg513 residue. Compound **10b** showed well interaction with Ser353 and Tyr355 which is going alongside with the screening results. Also, compound **12a** showed three binding interactions to Leu352, His90 and Val523 amino acid. Finally, compound **12b** binds to Ala527 and Tyr355 residues.

Conclusions {#Sec17}
===========

Some novel heterocyclic compounds **5a,b**--**14a,b** containing fluorine, chlorine, bromine and phosphorus elements were synthesized utilizing 3-substituted-4-amino-5-substituted amino-1,2,4-triazoles **3a-d** and 3-substituted-4-amino-5-hydrazino-1,2,4-triazole **9a,b** compounds as building units in the synthesizing process. These newly prepared compounds were fully characterized through the spectral and elemental analyses which were completely fit with the assigned structures. A number of the synthesized compounds were screened against gram-positive bacteria, gram-negative bacteria, and fungi, such as *Streptococcus aureus, Escherichia coli, Pseudomonas aeruginosa*, and *Candida albicans*. Most of the newly prepared compounds showed a high antibacterial, antifungal, and anti-inflammatory in comparing with the standard commercial antibiotics Imipenem and Nalidixic acid, Nystatin and Indomethacin, respectively. Compounds **10a,b**, and **12a,b** containing both chlorine and fluorine elements showed high inflammation activity.
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